Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.

@article{Serkova2005DetectionOR,
  title={Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.},
  author={Natalie J. Serkova and L{\'a}szl{\'o} G. Boros},
  journal={American journal of pharmacogenomics : genomics-related research in drug development and clinical practice},
  year={2005},
  volume={5 5},
  pages={293-302}
}
Acquired resistance to imatinib mesylate is an increasing and continued challenge in the treatment of BCR-ABL tyrosine kinase positive leukemias as well as gastrointestinal stromal tumors. Stable isotope-based dynamic metabolic profiling (SIDMAP) studies conducted in parallel with the development and clinical testing of imatinib revealed that this targeted drug is most effective in controlling glucose transport, direct glucose oxidation for RNA ribose synthesis in the pentose cycle, as well as… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…